Aussie HIV/AIDS Groups Protest Coverage Delays For Hepatitis B Tests
This article was originally published in PharmAsia News
Executive SummaryHIV/AIDS groups in Australia accuse the federal government of unnecessarily delaying for at least six years approval of coverage for a diagnostic for hepatitis B. The government relies on its Medical Services Advisory Committee to recommend federal funding for medical procedures based on their safety and effectiveness. Recently the HIV/AIDS and other groups have complained about the panel's lack of accountability for its approvals process. The HIV/AIDS groups noted it took three years to approve a procedure for determining a patient's hepatitis B viral load because the panel lost paperwork. (Click here for more
You may also be interested in...
MDSAP And USMCA: 3 Ways Mexico Can To Come Up-To-Speed With The Single-Audit Program Targeted By New Free-Trade Accord
The US-Mexico-Canada (USMCA) treaty calls for the three countries to “recognize audits” performed under the Medical Device Single Audit Program. MDSAP is already used by device makers in the US and Canada so they can undergo one audit by an accredited third party to satisfy quality regulations. That leaves Mexico as the odd country out when it comes to using the popular program – and that means it has some catching up to do after the USMCA is ratified by all three nations. Former longtime FDA official Kim Trautman weighs in on how Mexico can incorporate MDSAP into its regulatory framework.
Genomic profiling firm Foundation Medicine hires new chief commercial officer; Bardy Diagnostics, developer of cardiac arrhythmia devices, picks a chief operating officer; Lantheus Medical Imaging, producer of diagnostic imaging agents and products; brings aboard a new chief medical officer; and more.